Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: J Eur Acad Dermatol Venereol. 2020 Feb 5;34(6):1340–1347. doi: 10.1111/jdv.16159

Figure 2.

Figure 2.

Patients with dAEs attributed to kinase-targeted therapy (a) 43-year-old woman with lung cancer and interruption of treatment with EGFR inhibitor due to grade 2 maculopapular rash (b) 72-year-old man with mesothelioma and interruption of anti-ERK agent due to grade 2 maculopapular rash (c) 67-year-old man with prostate cancer and interruption of mTOR protein targeted therapy due to grade 3 maculopapular rash.